Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 283

Related Citations for PubMed (Select 15452302)

1.

The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.

Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM.

Neurology. 2004 Sep 28;63(6):1079-80.

PMID:
15452302
2.

The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.

Strupp M.

Neurology. 2005 Mar 22;64(6):1100; author reply 1100. No abstract available.

PMID:
15781847
3.

Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.

Perumal JS, Caon C, Hreha S, Zabad R, Tselis A, Lisak R, Khan O.

Eur J Neurol. 2008 Jul;15(7):677-80. doi: 10.1111/j.1468-1331.2008.02146.x. Epub 2008 May 6.

PMID:
18459972
4.

Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.

Zivadinov R, Zorzon M, De Masi R, Nasuelli D, Cazzato G.

J Neurol Sci. 2008 Apr 15;267(1-2):28-35. Epub 2007 Oct 18.

PMID:
17945260
5.

Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis.

Metz LM, Sabuda D, Hilsden RJ, Enns R, Meddings JB.

Neurology. 1999 Dec 10;53(9):2093-6.

PMID:
10599787
6.

Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission.

Faure C, André J, Pelatan C, Munck A, Giraud M, Cèzard JP, Jacqz-Aigrain E.

Eur J Clin Pharmacol. 1998 Sep;54(7):555-60.

PMID:
9832298
7.

Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats.

Konishi H, Sumi M, Shibata N, Takada K, Minouchi T, Yamaji A.

J Pharm Pharmacol. 2004 Oct;56(10):1259-66.

PMID:
15482640
8.

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M; ACT Investigators.

Neurology. 2009 Feb 10;72(6):535-41. doi: 10.1212/01.wnl.0000341934.12142.74.

PMID:
19204263
9.

[Steroid therapy for multiple sclerosis].

Oishi C, Sakuta M.

Nihon Rinsho. 2003 Aug;61(8):1361-6. Review. Japanese.

PMID:
12962024
10.
11.

Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses.

Chapman C, Tubridy N, Cook MJ, Mitchell PJ, MacGregor LR, Lovelock C, Litewka L, Sedal L, Kilpatrick TJ, Butzkueven H.

J Clin Neurosci. 2006 Jul;13(6):636-8. Epub 2006 Jun 21.

PMID:
16790352
13.

Follow-up study of MS patients treated with high-dose intravenous methylprednisolone.

Frequin ST, Lamers KJ, Barkhof F, Borm GF, Hommes OR.

Acta Neurol Scand. 1994 Aug;90(2):105-10.

PMID:
7801735
14.

What we have learned from the Optic Neuritis Treatment Trial.

Beck RW, Trobe JD.

Ophthalmology. 1995 Oct;102(10):1504-8. No abstract available.

PMID:
9097798
15.

Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury.

Barth J, Winkler J, Schumann R, Nagaraja NV, Madabushi R, Balbach S, Derendorf H, Möllmann H, Möllenhoff G.

Int J Clin Pharmacol Ther. 2004 Sep;42(9):504-11.

PMID:
15487809
16.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
17.

Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses.

Ferry JJ, Horvath AM, Bekersky I, Heath EC, Ryan CF, Colburn WA.

J Clin Pharmacol. 1988 Jan;28(1):81-7.

PMID:
3350994
18.
19.

Pulse glucocorticoid therapy. The 'big shot' revisited.

Roujeau JC.

Arch Dermatol. 1996 Dec;132(12):1499-502.

PMID:
8961881
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk